Quantrill S J, Woodhead M A, Bell C E, Hardy C C, Hutchison A J, Gokal R
Dept of Respiratory Medicine, Manchester Royal Infirmary, UK.
Eur Respir J. 2002 Aug;20(2):440-3. doi: 10.1183/09031936.02.00298002.
Patients with chronic renal failure (CRF) have a high incidence of tuberculosis (TB). Those from the Indian subcontinent are at particular risk. The frequency of side-effects associated with antituberculous treatment in a group of patients with CRF was studied. All cases of TB in patients with CRF occurring over a 13-yr period at the Manchester Royal Infirmary, from 1986-1999, were identified by diagnostic coding, microbiology records and a TB database. The case notes were then reviewed. Twenty-four cases were identified, eight predialysis and 16 requiring regular dialysis. TB occurring in the dialysis group was extrapulmonary in every case. Nineteen of 24 (79%) patients were of Indian subcontinent origin and 14 of 16 (87%) dialysis patients were non-Caucasian. Adverse effects of treatment occurred in two of eight (25%) in the predialysis group and nine of 16 (56%) of the dialysis group. These were most commonly neuropsychiatric (6), hepatic (4) and gastrointestinal (4). Neuropsychiatric symptoms occurred exclusively in dialysis patients. In conclusion, a high incidence of side-effects from antituberculous medication, especially neuropsychiatric, hepatic and gastrointestinal, was identified in patients with chronic renal failure. Careful monitoring for side-effects is essential in this group, and consideration should be given to administering antituberculous chemoprophylaxis to all high-risk groups.
慢性肾衰竭(CRF)患者结核病(TB)发病率较高。来自印度次大陆的患者风险尤为突出。本研究调查了一组慢性肾衰竭患者抗结核治疗相关副作用的发生频率。通过诊断编码、微生物学记录以及结核病数据库,确定了1986年至1999年在曼彻斯特皇家医院13年间发生的所有慢性肾衰竭患者的结核病病例。随后对病例记录进行了复查。共确定了24例病例,其中8例为透析前患者,16例需要定期透析。透析组发生的结核病均为肺外结核。24例患者中有19例(79%)来自印度次大陆,16例透析患者中有14例(87%)为非白种人。透析前组8例中有2例(25%)出现治疗不良反应,透析组16例中有9例(56%)出现不良反应。这些不良反应最常见的是神经精神方面(6例)、肝脏方面(4例)和胃肠道方面(4例)。神经精神症状仅出现在透析患者中。总之,在慢性肾衰竭患者中,抗结核药物的副作用发生率较高,尤其是神经精神、肝脏和胃肠道方面。对该组患者进行仔细的副作用监测至关重要,并且应考虑对所有高危人群进行抗结核化学预防。